Diffuse Large B-Cell Lymphoma
Conditions
Keywords
Relapsed, refractory, DLBCL
Brief summary
The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or resistant Diffuse Large B Cell Lymphoma (DLBCL) to assess the safety and efficacy of this strategy as a bridge to allogeneic transplantation.
Detailed description
Patients with Diffuse Large B Cell Lymphoma (DLBCL) resistant to or relapsing following rituximab-containing chemotherapy regimens have a poor prognosis. Patients may receive salvage chemotherapy and possibly an autologous stem cell transplant (auto-SCT). A proportion of these patients, however, will not respond to the chemotherapy or may relapse after the auto-SCT and therefore require novel treatment options. Such patients may benefit from an allogeneic stem cell transplantation (allo-STC). In this study the investigators aim to administer CAR19 T-cells to act as a bridge to the transplant strategy. Specifically, (1) the feasibility of generating CD19 specific Chimeric Antigen Receptor T-cells called CAR19 T-cells, (2) the safety of administering the CD19 CAR T-cells in this setting, (3) how well the CAR19 T-cells engraft and (4) to evaluate how effective these cells are as a bridge to allogeneic transplantation. Following informed consent and registration to the trial, patients will undergo an unstimulated leucapheresis for generation of the CAR19 T cells. Whilst the cells are being generated, patients will proceed with a further cycle of standard salvage (recommended ifosfamide, epirubicin and etoposide (i.e. the IVE regime), and should not receive rituximab. Patients will receive pre-conditioning with intravenous fludarabine and cyclophosphamide prior to infusion of a single dose of CAR-modified T-cells. An escalating dose protocol will be employed to identify a minimum effective dose of CAR19 T-cells.
Interventions
PROCEDURELeukapheresis
Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
DRUGCyclophosphamide
Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
DRUGFludarabine
Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
BIOLOGICALCAR19 T-Cells
The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration. Three dose cohorts are planned: * Dose Level 1: 2x105 CAR19 T-cells/kg * Dose Level 2: 1x106 CAR19 T-cells/kg * Dose Level 3: 5x106 CAR19 T-cells/kg
Sponsors
University College, London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 16-65 years 2. Confirmed diagnosis of CD19+ DLBCL 3. Primary resistant or relapsed disease failing to achieve metabolic Complete Response (CR) to 1st line salvage, or relapse post autograft failing to achieve metabolic CR following a single further cycle of salvage 4. Potential allogeneic transplant candidate 5. Agreement to have a pregnancy test, use adequate contraception for 12 months post-CAR19 T-cell infusion 6. Karnofsky performance status \>60 7. Written informed consent
Exclusion criteria
1. Women who are pregnant or lactating 2. Prior allogeneic transplantation 3. Progressive disease following most recent salvage prior to planned leucapheresis (those with mixed response are eligible) 4. Prior history of ischaemic heart disease, dysrhythmias, abnormal electrocardiogram (ECG)(Left Bundle Branch Block (LBBB)), Multiple Gated Acquisition (MUGA) left ventricular ejection fraction (LVEF) \<40% 5. Exclusions for proceeding to allogeneic transplantation (active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV); liver function test (LFT) \>3 x upper limit of normal (ULN); Creatinine Clearance (CrCl) \<40 ml/min; or other comorbidity that precludes transplantation) 6. Known central nervous system (CNS) involvement or cerebral vascular accident (CVA) within prior 3 months 7. Patients receiving corticosteroids at a dose of \> 10mg prednisolone per day (or equivalent) 8. Use of rituximab within the last 2 months prior to CAR19 T-cell infusion 9. Active autoimmune disease requiring immunosuppression 10. Life expectancy \<3 months 11. Known allergy to albumin or dimethylsulfoxide (DMSO) 12. Any contraindication to the administration and use of ifosfamide, epirubicin, etoposide, fludarabine and cyclophosphamide.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of adequate leucapheresis collection and generation of CAR19 T cells. | 1 month | The number of CAR19 T cells successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients registered). |
| Toxicity evaluation following CAR19 T-cell administration. | 1 year | Toxicity will be examined for each patient receiving CAR19 T cells, using the maximum grade for each toxicity type, all summarized as number of patients with adverse events. |
| Efficacy of CAR19 T-cells. | 1 year | Efficacy will be defined as the number of patients that meet the clinical complete responders criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical complete response | 1 month | 4\. Clinical response evaluated using standard PET-CT criteria at day 28 compared to baseline scan. Proportion of patients with complete response will be calculated. |
| CAR19 T-cell engraftment | 1 year | 1\. Engraftment, expansion and persistence of CAR19 T-cells. Detection of any level of CAR19 expression in circulating T cells (ie PBMC) by quantitative polymerase chain reaction (qPCR) and flow cytometry following infusion. |
| Eligibility to allogeneic transplantation | 1-3 years | 5\. Number of patients proceeding to allogeneic transplantation out of all patients registered to the trial, and also only for those who received CAR19 T cells. |
| B cell compartment | 1 year | 2\. Depletion of B cell compartment. The percentage reduction from baseline. Absolute B cell numbers measured by flow of PBMC (cells/ul) . |
| Cytokine profile | 1 year | 3\. Timing and magnitude of cytokine release. Data on timing (kinetic of change) as the mean (or median) amount of cytokine (pg/ml) over a number of days post-infusion. Using the individual patient data, the mean (or median) time to peak value can be obtained. Magnitude - kinetic and peak of cytokine levels, notably Tumour Necrosis Factor-alpha (TNF-a), Interleukin- 6 (IL-6) and Interferon-gamma (IFN-g) (pg/ml), can be plotted for each patient, as means (or medians). |
Countries
United Kingdom
Outcome results
None listed